🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Two posters of distinction on the same day! Michigan Hepatology Liver/Intestinal Community of Practice - AST Jasmohan Bajaj HRS Harmony Allison Kwong Scott biggins Sumeet Asrani AASLD #TLM24

High yield pearls about Hepatic encephalopathy at the State of Art Lecture #TLM24 by Jasmohan Bajaj 🧠 📌 First decompensating event in MASLD cirrhosis 🩺 Screen and treat other comorbid conditions like OSA (STOP BANG), dementia (MOCA), alcohol related (AUDIT-C) 🍻 ⬆️⬇️

Congratulations to Syed Ahmed, MD, DM (Gastro) for presenting his thesis work on carvedilol in CSPH.. based on Non invasive test (LSM >20kpa) used for prevention of decompensation.AASLD Anand V Kulkarni Sridhar Sundaram MD, DM, FISG Yujun_Wong Sanchit

Our Vinay Jahagirdar presenting “Initiation of naltrexone is associated with lower rates of AKI, SBP, and mortality in patients with decompensated alcohol-associated cirrhosis and ascites” at #TLM24 AASLD VCU Stravitz-Sanyal Institute for Liver Disease #LiverTwitter

Loved working on this project with Vinay Jahagirdar. From a phone call after DDW to: ✅ a great presentation 👨🏽‍🏫 ✅ a wonderful new friendship🕺 Deepika Devuni MD #TLM24

Initial ESSENCE data we shared today at #TLM24 demonstrate that semaglutide 2.4mg slows MASH progression and reverses existing liver damage. The ESSENCE data may represent key findings for patients in the treatment of #MASH. #livertwitter @aasldtweets Novo Nordisk Phil Newsome

Outstanding presentation by Philip Newsome from King’s College Exciting early results from ESSENCE trial Semaglutide vs Placebo More hope for MASH #TLM24

📢 Live from #TLM2024 The highly awaited semaglutide results in MASLD by P. Newsome. Impressive results from the first 800 patients who completed follow-up in the phase 3 study ESSENCE 👇🏻 AASLD

Wonderful day with wonderful speakers at our 18th Annual Southwest Liver Disease Symposium, hosted by Banner Transplant Institute! 🌵🏜️ Guadalupe GarciaTsao Marc Ghany, M.D. Ashley Spann Nadim Mahmud Fasiha Kanwal thank you all for enlightening us with your brilliant talks! 🗣️🎓

Hepatitis B tip Entecavir: empty stomach Tenofovir: with food From THE Norah Terrault GUILD Conference

What a day in the history of MASH! Reversal of Fibrosis in MASH cirrhotics by 24% (paired) and 17% (ITT) all sig P values. Same for NITs!!!! Happy for the our patients. FGF21s are here to stay!! #livertwitter Elliot Tapper Naim Alkhouri akerotx globenewswire.com/news-release/2…

🧵Just released! Our The Lancet Gastroenterology & Hepatology review explores the latest AUD management from a gastro/hepatology perspective 👉authors.elsevier.com/c/1kc078nByrCi…. ⬇️ Juan Pablo (JP) Arab, MD  Ramon Bataller Lorenzo Leggio MASLD Research Center UCSD Gastroenterology Facultad Medicina UC #LiverTwitter ALEH AASLD EASL Education

In this interim analysis of a phase 3 trial involving 800 patients with metabolic dysfunction–associated steatohepatitis, once-weekly semaglutide improved liver histologic results at 72 weeks. Full ESSENCE trial results: nej.md/3EVFAFM

Breaking! Phase 3 ESSENCE trial results just out: Semaglutide 2.4 mg showed significant improvements for adults with #MASH-63% achieved resolution of steatohepatitis with no worsening of fibrosis vs. 34% on placebo at 72 weeks. #LiverHealth nejm.org/doi/full/10.10… NEJM

Very important paper led by Arun J. Sanyal In patients with MASH and F2-3, once-weekly semaglutide at a dose of 2.4 mg improved liver histologic results. The findings in fibrosis are very interesting and encouraging, let’s go now for ALD! #LiverTwitter #LiverX

Please Join us on May 4 8-9:30 am to discuss Novel MASLD biomarkers. eppro01.ativ.me/appinfo.php?pa… #DDW2025 Mike Fallon, MD UACOM-P Transplant Hepatology Fellowship Digestive Disease Week

Please stop by our research poster today at Halls C-E to explore "Incident of Liver Related Events and Transplant in MASLD patients undergoing Pharmacologic vs Bariatric interventions." Leith Ghani, DO Diwanshu Soni Mike Fallon, MD UACOM-P Transplant Hepatology Fellowship #DDW2025 Digestive Disease Week®

Huge congrats to my fabulous residents and student for nailing our research project presentation today Leith Ghani, DO Diwanshu Soni Mike Fallon, MD UACOM-P Transplant Hepatology Fellowship UAZ Medicine - Phoenix #DDW2025 Digestive Disease Week

Chill with current and alumni Fellows and watch them flourish. It's awesome to see them grow UACOM-P Transplant Hepatology Fellowship Mike Fallon, MD UAZ Medicine - Phoenix Digestive Disease Week #DDW2025

It's an honor to serve as a moderator for Novel MASLD biomarkers. Congratulations to the presenters on their outstanding research in utilizing biomarkers to predict and stratify MASLD. #DDW2025 Digestive Disease Week UAZ Medicine - Phoenix UAZ Medicine - Phoenix UACOM-P Transplant Hepatology Fellowship